Matthew Taylor
Stock Analyst at UBS
(2.73)
# 2,120
Out of 5,081 analysts
182
Total ratings
62.73%
Success rate
11.37%
Average return
Main Sectors:
Stocks Rated by Matthew Taylor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PODD Insulet | Maintains: Neutral | $320 → $355 | $307.56 | +15.42% | 16 | Nov 7, 2025 | |
| EW Edwards Lifesciences | Upgrades: Buy | $80 → $98 | $83.98 | +16.69% | 20 | Oct 29, 2025 | |
| SI Shoulder Innovations | Initiates: Buy | $19 | $15.23 | +24.75% | 1 | Aug 25, 2025 | |
| ABT Abbott Laboratories | Upgrades: Buy | $143 → $145 | $125.29 | +15.73% | 17 | Jul 18, 2025 | |
| INMD InMode | Maintains: Hold | $16 → $15 | $14.44 | +3.88% | 7 | Apr 14, 2025 | |
| GEHC GE HealthCare Technologies | Upgrades: Buy | $95 → $103 | $83.59 | +23.22% | 2 | Jan 8, 2025 | |
| MDT Medtronic | Maintains: Sell | $75 → $76 | $101.97 | -25.47% | 17 | May 24, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $125 | $1.59 | +7,761.64% | 1 | Feb 9, 2024 | |
| MASI Masimo | Downgrades: Hold | $107 → $121 | $138.09 | -12.38% | 9 | Jan 30, 2024 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $14 | $4.86 | +188.07% | 1 | Jan 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $45 | $19.93 | +125.79% | 2 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $10 | $6.40 | +56.25% | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $58 → $53 | $13.48 | +293.18% | 2 | Jul 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $22 → $24 | $11.46 | +109.42% | 2 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $320 → $345 | $365.95 | -5.72% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Hold | $115 → $130 | $93.10 | +39.63% | 8 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $285.71 | -19.50% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $19.18 | +4.28% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $85 | $44.35 | +91.66% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $87.75 | -14.53% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $245 | $251.44 | -2.56% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $62 | $18.89 | +228.22% | 8 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $119.12 | +76.29% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $21.23 | -43.48% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $64.85 | +92.75% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $98.57 | -49.27% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $569.71 | -63.14% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $96 | $63.29 | +51.68% | 3 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $7 | $2.97 | +135.69% | 1 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $266 | $193.57 | +37.42% | 4 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $16 | $13.49 | +18.61% | 2 | Jul 19, 2017 |
Insulet
Nov 7, 2025
Maintains: Neutral
Price Target: $320 → $355
Current: $307.56
Upside: +15.42%
Edwards Lifesciences
Oct 29, 2025
Upgrades: Buy
Price Target: $80 → $98
Current: $83.98
Upside: +16.69%
Shoulder Innovations
Aug 25, 2025
Initiates: Buy
Price Target: $19
Current: $15.23
Upside: +24.75%
Abbott Laboratories
Jul 18, 2025
Upgrades: Buy
Price Target: $143 → $145
Current: $125.29
Upside: +15.73%
InMode
Apr 14, 2025
Maintains: Hold
Price Target: $16 → $15
Current: $14.44
Upside: +3.88%
GE HealthCare Technologies
Jan 8, 2025
Upgrades: Buy
Price Target: $95 → $103
Current: $83.59
Upside: +23.22%
Medtronic
May 24, 2024
Maintains: Sell
Price Target: $75 → $76
Current: $101.97
Upside: -25.47%
Allurion Technologies
Feb 9, 2024
Initiates: Buy
Price Target: $125
Current: $1.59
Upside: +7,761.64%
Masimo
Jan 30, 2024
Downgrades: Hold
Price Target: $107 → $121
Current: $138.09
Upside: -12.38%
Orchestra BioMed Holdings
Jan 19, 2024
Initiates: Buy
Price Target: $14
Current: $4.86
Upside: +188.07%
Oct 2, 2023
Maintains: Buy
Price Target: $47 → $45
Current: $19.93
Upside: +125.79%
Jul 19, 2023
Initiates: Underperform
Price Target: $10
Current: $6.40
Upside: +56.25%
Jul 12, 2023
Upgrades: Buy
Price Target: $58 → $53
Current: $13.48
Upside: +293.18%
May 24, 2023
Maintains: Hold
Price Target: $22 → $24
Current: $11.46
Upside: +109.42%
May 2, 2023
Maintains: Buy
Price Target: $320 → $345
Current: $365.95
Upside: -5.72%
Mar 31, 2023
Upgrades: Hold
Price Target: $115 → $130
Current: $93.10
Upside: +39.63%
Oct 12, 2022
Initiates: Buy
Price Target: $230
Current: $285.71
Upside: -19.50%
Oct 12, 2022
Initiates: Buy
Price Target: $20
Current: $19.18
Upside: +4.28%
Oct 12, 2022
Initiates: Hold
Price Target: $85
Current: $44.35
Upside: +91.66%
Oct 12, 2022
Initiates: Buy
Price Target: $75
Current: $87.75
Upside: -14.53%
Oct 12, 2022
Initiates: Hold
Price Target: $245
Current: $251.44
Upside: -2.56%
Oct 12, 2022
Initiates: Hold
Price Target: $62
Current: $18.89
Upside: +228.22%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $119.12
Upside: +76.29%
Oct 12, 2022
Initiates: Buy
Price Target: $12
Current: $21.23
Upside: -43.48%
Oct 12, 2022
Initiates: Buy
Price Target: $125
Current: $64.85
Upside: +92.75%
Oct 12, 2022
Initiates: Buy
Price Target: $50
Current: $98.57
Upside: -49.27%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $569.71
Upside: -63.14%
Feb 24, 2022
Upgrades: Buy
Price Target: $96
Current: $63.29
Upside: +51.68%
Dec 17, 2021
Initiates: Neutral
Price Target: $7
Current: $2.97
Upside: +135.69%
May 13, 2019
Upgrades: Overweight
Price Target: $266
Current: $193.57
Upside: +37.42%
Jul 19, 2017
Maintains: Equal-Weight
Price Target: $17 → $16
Current: $13.49
Upside: +18.61%